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POLYPEPTIDES, NUCLEIC ACID
MOLECULES, AND METHODS FOR

SUMMARY

SYNTHESIS OF TRITERPENES

The presently-disclosed subject matter meets some or all of
the above-identi?ed needs, as will become evident to those of

RELATED APPLICATIONS

ordinary skill in the art after a study of information provided
in this document.
This Summary describes several embodiments of the pres
ently-disclosed subject matter, and in many cases lists varia

This application claims priority from US. Provisional
Application Ser. No. 61/517,876 ?led Apr. 27, 2011, the

tions and permutations of these embodiments. This Summary
is merely exemplary of the numerous and varied embodi

entire disclosure of which is incorporated herein by this ref
erence.

ments. Mention of one or more representative features of a

given embodiment is likewise exemplary. Such an embodi

GOVERNMENT INTEREST

This invention was made with government support under
Grant No. CBET-0828817 awarded by the National Science
Foundation and under grant number 2P20 RR020171 from
the National Center for Research Resources of the National
Institutes of Health. The government has certain rights in the
invention.

ment can typically exist with or without the feature(s) men

tioned; likewise, those features can be applied to other

embodiments of the presently-disclosed subject matter,
whether listed in this Summary or not. To avoid excessive

repetition, this Summary does not list or suggest all possible
combinations of such features.

Botryococcene biosynthesis is thought to resemble that of
20

TECHNICAL FIELD

The presently-disclosed subject matter relates to composi
tions and methods for triterpene synthesis, in particular bot
ryococcene synthesis.

two molecules of farnesyl diphosphate (FPP) to form pre
squalene diphosphate (PSPP), which then undergoes a reduc
tive rearrangement to form squalene. In principle, botryococ
25

Botryococcus braunii is a colony-forming, freshwater
green algae reported to accumulate 30 to 86% of its dry
weight as hydrocarbon oils (1). Three distinct races of B.
braunii have been described based on the types of hydrocar
bons that each accumulates (2). Race A accumulates fatty

30

acid-derived alkadienes and alkatrienes (3), race L accumu

35

lated squalene synthase-like genes from B. braunii race B.
While B. braunii does harbor at least one typical squalene

synthase, none of the other three squalene synthase-like

(SSL) genes encode for botryococcene biosynthesis directly.
SSL-l catalyzes the biosynthesis of PSPP and SSL-2 the
biosynthesis of bisfamesyl ether, while SSL-3 does not

lates the tetraterpene lycopadiene (4), and race B accumulates

triterpenes, predominately botryococcene, squalene and their

appear able to directly utilize FPP as a substrate. However,
when combinations of the synthase-like enzymes were mixed

together, in vivo and in vitro, robust botryococcene (SSL-1+
SSL-3) or squalene biosynthesis (SSL1+SSL-2) was
observed. These ?ndings were unexpected because squalene

methylated derivatives (5). The oils accumulate both in intra
cellular oil bodies and in association with an extracellular
40

synthase, an ancient and likely progenitor to the other B02

ryococcus triterpene synthases, catalyzes a two-step reaction

polymethylsqualene diols (7). Di- and tetra-methylated bot

within a single enzyme unit without intermediate release, yet
in B. braunii, these activities appear to have separated and

ryococcenes are generally the most abundant triterpenes
accumulating in race B with smaller amounts of tetramethy

lated-squalene (8) and other structural derivatives of squalene
and botryococcene that range from C31 to C37 accumulating

cene could arise from an alternative rearrangement of the

pre-squalene intermediate. Because of these proposed simi
larities, the present inventors predicted that a botryococcene
synthase would resemble squalene synthase and hence iso

INTRODUCTION

matrix (6), which in race B consists largely of long-chain,
cross-linked biopolymers formed in part from acetalization of

squalene, a metabolite essential for sterol metabolism in all
eukaryotes. Squalene arises from an initial condensation of

evolved inter-dependently for specialized triterpene oil pro
45

duction greater than 500 MYA. Co-expression of the SSL-l
and SSL-3 genes in different con?gurations, as independent

to various levels in different strains and in response to variable

genes, as gene fusions, or targeted to intracellular mem

culture conditions (9). Other polymethylated derivatives such

branes, also demonstrate the potential for engineering even

as diepoxy-tetramethylsqualene (10), botryolins (11), and
brauixanthins (12) have also been reported.

greater ef?ciencies of botryococcene biosynthesis.
50

The presently-disclosed subject matter includes an isolated

B. braunii race B has received signi?cant attention because

polypeptide having triterpene synthase activity wherein the

it is considered an ancient algal species dating back at least

polypeptide includes a peptide domain selected from
domains I, II, III, IV, and V, wherein domain I comprises an

500 MYA and is one of the few organisms known to have

directly contributed to the existing oil and coal shale deposits
found on Earth (13-15), accounting for up to 1.4% of the total

amino acid sequence that is at least 60% identical to the amino
55

acid sequence of SEQ ID NO: 17, domain II comprises an

hydrocarbon content in oil shales (16). Secondly, because the

amino acid sequence that is at least 60% identical to the amino

hydrocarbon oils of B. braunii race B are readily converted to

acid sequence of SEQ ID NO: 18, domain III comprises an

starting materials for industrial chemical manufacturing and

amino acid sequence that is at least 60% identical to the amino

high quality fuels under standard hydrocracking/distillation
conditions in yields approaching 97% (FIG. 1A) (17), race B

acid sequence of SEQ ID NO: 19, domain IV comprises an
60

amino acid sequence that is at least 60% identical to the amino

has been considered a potential production host for renewable

acid sequence of SEQ ID NO: 20, and domainV comprises an

petrochemicals and biofuels. However, the slow growth habit

amino acid sequence that is at least 60% identical to the amino
acid sequence of SEQ ID NO: 21. In some embodiments of

of B. braunii poses serious limitations to its suitability as a

robust biofuel production system.
There remains a need in the art to harness this unique oil
biosynthetic capacity for use in a system that allows for more

rapid and higher yield production.

65

the isolated polypeptide, domain I comprises the amino acid
sequence of SEQ ID NO: 17, domain II comprises the amino
acid sequence of SEQ ID NO: 18, domain III comprises the
amino acid sequence of SEQ ID NO: 19, domain IV com

US 8,822,187 B1
3

4

prises the amino acid sequence of SEQ ID NO: 20, and
domainV comprises the amino acid sequence of SEQ ID NO:

amino acid sequence of SEQ ID NO: 14. In some embodi

ments the polypeptide comprises peptide domains I, II, III, IV,

polypeptide comprises peptide domains I, II, III, IV, andV. In

and V. In some embodiments the polypeptide has the amino
acid sequence of SEQ ID NO: 9. In some embodiments, the

some embodiments, the isolated polypeptide includes the

polypeptide has triterpene synthase activity. In some embodi

21. In some embodiments of the isolated polypeptide, the

amino acid sequence of SEQ ID NO: 16. In some embodi

ments, the polypeptide comprises an amino acid sequence

ments, the polypeptide has triterpene synthase activity. In

that is at least 60% identical to the amino acid sequence of

some embodiments, the isolated polypeptide includes an
amino acid sequence that is at least 60% identical to the amino

SEQ ID NO: 9.
The presently-disclosed subject matter further includes an

acid sequence of SEQ ID NO: 16.

isolated nucleic acid, encoding the polypeptide comprising a
peptide domain selected from domains I, II, III, IV, and V,

The presently-disclosed subject matter furthering includes
an isolated nucleic acid, encoding the polypeptide including a

peptide domain selected from domains I, II, III, IV, and V,
Wherein domainI comprises an amino acid sequence that is at
least 60% identical to the amino acid sequence of SEQ ID
NO: 17, domain II comprises an amino acid sequence that is
at least 60% identical to the amino acid sequence of SEQ ID
NO: 18, domain III comprises an amino acid sequence that is
at least 60% identical to the amino acid sequence of SEQ ID
NO: 19, domain IV comprises an amino acid sequence that is
at least 60% identical to the amino acid sequence of SEQ ID
NO: 20, and domainV comprises an amino acid sequence that
is at least 60% identical to the amino acid sequence of SEQ ID
NO: 21. In some embodiments the isolated nucleic acid fur

ther encodes a second polypeptide having triterpene synthase
activity Wherein the second polypeptide comprises a peptide
domain selected from domains I, II, III, IV, and V, Wherein
domain I comprises an amino acid sequence that is at least
65% identical to the amino acid sequence of SEQ ID NO: 3,
domain II comprises an amino acid sequence that is at least
65% identical to the amino acid sequence of SEQ ID NO: 4,
domain III comprises an amino acid sequence that is at least
60% identical to the amino acid sequence of SEQ ID NO: 5,
domain IV comprises an amino acid sequence that is at least
80% identical to the amino acid sequence of SEQ ID NO: 6,
and domain V comprises an amino acid sequence that is at
least 60% identical to the amino acid sequence of SEQ ID
NO: 7. In some embodiments of the presently-disclosed sub
ject matter a vector comprising the nucleic acid(s) is pro
vided.

20

25

30

35

encodes a second polypeptide having triterpene synthase
activity Wherein the second polypeptide comprises a peptide
domain selected from domains I, II, III, IV, andV, Wherein:
domain I comprises an amino acid sequence that is at least
65% identical to the amino acid sequence of SEQ ID NO: 3,
domain II comprises an amino acid sequence that is at least
65% identical to the amino acid sequence of SEQ ID NO: 4,
domain III comprises an amino acid sequence that is at least
60% identical to the amino acid sequence of SEQ ID NO: 5,
domain IV comprises an amino acid sequence that is at least
80% identical to the amino acid sequence of SEQ ID NO: 6,
and domain V comprises an amino acid sequence that is at
least 60% identical to the amino acid sequence of SEQ ID
NO: 7. In some embodiments of the presently-disclosed sub
ject matter a vector comprising the nucleic acid(s) is pro
vided.

In some embodiments of the presently-disclosed subject
40

In some embodiments of the presently-disclosed subject
matter a host cell transfected With the nucleic acid(s) is pro
vided. In some embodiments, the host cell is further trans
fected With a nucleic acid molecule encoding a famesyl

diphosphate synthase, a triterpene methyltransferase, a
squalene methyltransferase, or a botryococcene methyltrans

Wherein: domain I comprises an amino acid sequence that is
at least 60% identical to the amino acid sequence of SEQ ID
NO: 10, domain II comprises an amino acid sequence that is
at least 60% identical to the amino acid sequence of SEQ ID
NO: 11, domain III comprises an amino acid sequence that is
at least 60% identical to the amino acid sequence of SEQ ID
NO: 12, domain IV comprises an amino acid sequence that is
at least 60% identical to the amino acid sequence of SEQ ID
NO: 13, and domainV comprises an amino acid sequence that
is at least 60% identical to the amino acid sequence of SEQ ID
NO: 14. In some embodiments, the nucleic acid further

matter a host cell transfected With the nucleic acid(s) is pro
vided. In some embodiments, the host cell is further trans
fected With a nucleic acid molecule encoding a famesyl

diphosphate synthase, a triterpene methyltransferase, a
squalene methyltransferase, or a botryococcene methyltrans
45

ferase.
The presently-disclosed subject matter further includes a

ferase.
In some embodiments of the presently-disclosed subject

method for producing triterpenes including: (a) providing a

matter an isolated polypeptide having triterpene synthase
activity Wherein the polypeptide comprises a peptide domain
selected from domains I, II, III, IV, andV, Wherein: domainI

having triterpene synthase activity Wherein the polypeptide

comprises an amino acid sequence that is at least 60% iden
tical to the amino acid sequence of SEQ ID NO: 10, domain
II comprises an amino acid sequence that is at least 60%
identical to the amino acid sequence of SEQ ID NO: 11,
domain III comprises an amino acid sequence that is at least
60% identical to the amino acid sequence of SEQ ID NO: 12,
domain IV comprises an amino acid sequence that is at least
60% identical to the amino acid sequence of SEQ ID NO: 13,
and domain V comprises an amino acid sequence that is at
least 60% identical to the amino acid sequence of SEQ ID
NO: 14. In some embodiments of the isolated polypeptide
domainI comprises the amino acid sequence of SEQ ID NO:
10, domain II comprises the amino acid sequence of SEQ ID
NO: 11, domain III comprises the amino acid sequence of
SEQ ID NO: 12, domain IV comprises the amino acid
sequence of SEQ ID NO: 13, and domain V comprises the

cell transfected With (i) a nucleic acid encoding a polypeptide
50

comprises a peptide domain selected from domains I, II, III,
IV, and V, Wherein: domain I comprises an amino acid
sequence that is at least 60% identical to the amino acid

sequence of SEQ ID NO: 17, domain II comprises an amino
acid sequence that is at least 60% identical to the amino acid
55

sequence of SEQ ID NO: 18, domain III comprises an amino
acid sequence that is at least 60% identical to the amino acid

sequence of SEQ ID NO: 19, domain IV comprises an amino
acid sequence that is at least 60% identical to the amino acid

sequence of SEQ ID NO: 20, and domain V comprises an
60

amino acid sequence that is at least 60% identical to the amino
acid sequence of SEQ ID NO: 21; or (ii) a nucleic acid

encoding a polypeptide having triterpene synthase activity
Wherein the polypeptide comprises a peptide domain selected
from domains I, II, III, IV, and V, Wherein: domain I com
65

prises an amino acid sequence that is at least 60% identical to
the amino acid sequence of SEQ ID NO: 10, domain II com
prises an amino acid sequence that is at least 60% identical to

US 8,822,187 B1
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the amino acid sequence of SEQ ID NO: 11, domain III

combustion engines; brie?y, botryococcenes are treated with
high pressure H2 at high temperatures with a Pd catalyst to
give a variety of organic molecules, which can be further

comprises an amino acid sequence that is at least 60% iden
tical to the amino acid sequence of SEQ ID NO: 12, domain
IV comprises an amino acid sequence that is at least 60%
identical to the amino acid sequence of SEQ ID NO: 13, and
domain V comprises an amino acid sequence that is at least
60% identical to the amino acid sequence of SEQ ID NO: 14;

distilled into various classes of fuel.

FIG. 1B includes biosynthetic pathways for botryococcene
and squalene; both triterpenes are derived from an initial
condensation of two FPP molecules to form presqualene

and (b) culturing the transfected cell under conditions suit

diphosphate (PSPP), which is subsequently cleaved and

able for production of triterpenes.

reduced to form either botryococcene or squalene.
FIG. 2 includes an amino acid alignment of BSS (SEQ ID

In some embodiments of the method the cell is further
transfected with a second nucleic acid encoding a second

NO: 22), SSL-1 (SEQ ID NO: 2), SSL-2 (SEQ ID NO: 9), and

polypeptide having triterpene synthase activity wherein the

SSL-3 (SEQ ID NO: 16 from B. braunii race B. Five highly

second polypeptide comprises a peptide domain selected
from domains I, II, III, IV, and V, wherein: domain I com
prises an amino acid sequence that is at least 65% identical to
the amino acid sequence of SEQ ID NO: 3, domain II com
prises an amino acid sequence that is at least 65% identical to
the amino acid sequence of SEQ ID NO: 4, domain III com
prises an amino acid sequence that is at least 50% identical to
the amino acid sequence of SEQ ID NO: 5, domain IV com
prises an amino acid sequence that is at least 80% identical to

conserved domains amongst squalene synthase’s identi?ed
by Robinson et al. (Mol Cell Biol 13:2706-2717) and the
“FLAP” and putative NADPH binding site identi?ed by Gu et
al. (JBiol Chem 273:12515-12525) are boxed. Amino acids

20

completely conserved in the squalene synthase of B. braunii
(AF205791), C. reinhardlii (XM001703395), A. Zhaliana
(NM119630), N. Zabacum (U60057), H. sapiens
(NM004462), R. norvegicus (NM019238), S. cereviseae

0(59959), S. pombe (NM001021271), and Y. lipolylica

the amino acid sequence of SEQ ID NO: 6, and domain V
comprises an amino acid sequence that is at least 40% iden

(AF092497), plus those residues also conserved with these

tical to the amino acid sequence of SEQ ID NO: 7. In some

squalene synthases and dehydrosqualene synthase (CrtM)

embodiments, the method further includes isolating triter

from S. aureus (AM920687), are labeled above the align
ment. Residues of CrtM identi?ed by Lin et al. (Proc Natl
Acad Sci USA 107:21337-21342) as important for the ?rst

pene from the cultured cells.
The presently-disclosed subject matter further includes a

25

kit for producing triterpenes, including (a) a ?rst polypeptide

and second half reactions are labeled with a star. Possible

having triterpene synthase activity wherein the polypeptide

membrane spanning regions of BSS and SSL2 as predicted by
TMpred are underlined. In the subsequent studies, a 3' trun

comprises a peptide domain selected from domains I, II, III,
IV, and V, wherein: domain I comprises an amino acid

30

cated form of SSL2 (tr2) missing the putative membrane
spanning domain after D392 (indicated by arrow) was heter

sequence that is at least 60% identical to the amino acid
sequence of SEQ ID NO: 17 or at least 60% identical to the

ologously expressed in bacteria.

amino acid sequence of SEQ ID NO: 10, domain II comprises

FIG. 3 includes an alignment comparison of selection
regions/domains of sequence for Bolryococcus braunii race

an amino acid sequence that is at least 60% identical to the
amino acid sequence of SEQ ID NO: 18 or at least 60%

35

or at least 60% identical to the amino acid sequence of SEQ
ID NO: 12, domain IV comprises an amino acid sequence that
is at least 60% identical to the amino acid sequence of SEQ ID

Sequences displayed across the ?ve domains are: SSL1, SEQ

40

NO: 20 or at least 60% identical to the amino acid sequence of

SEQ ID NO: 13, and domain V comprises an amino acid
sequence that is at least 60% identical to the amino acid
sequence of SEQ ID NO: 21 or at least 60% identical to the

B squalene synthase-like 1, 2, and 3, (SSL-1, SSL-2, and

SSL-3), and Bolryococcus squalene synthase (BSS).

identical to the amino acid sequence of SEQ ID NO: 11,
domain III comprises an amino acid sequence that is at least
60% identical to the amino acid sequence of SEQ ID NO: 19

ID NO: 3, 4, 5, 6, and 7; SSL-2, SEQ ID NO: 10,11,12,13,
and 14; SSL-3, SEQ ID NO: 17, 18, 19, 20, and 21; and BSS,
SEQ ID NO: 23, 24, 25, 26, and 27.
FIG. 4 depicts the dependence of the squalene synthase
like-1 enzyme on algal lysate for botryococcene biosynthesis.
Puri?ed SSL-1 enzyme (1 pg) (SSL-1), B. braunii 2000 g

whole-cell lysate (10 pg protein) (Lys), and equal aliquots of
45

amino acid sequence of SEQ ID NO: 14; and (b) a second

both SSL-1 and lysate were incubated with radiolabeled FPP,
with (+) or without (—) 2 mM NADPH and the incorporation

polypeptide having triterpene synthase activity wherein the

into squalene and botryococcene determined by TLC separa

second polypeptide comprises a peptide domain selected
from domains I, II, III, IV, and V, wherein: domain I com

tion of the reaction products followed by scintillation count

prises an amino acid sequence that is at least 65% identical to
the amino acid sequence of SEQ ID NO: 3, domain II com
prises an amino acid sequence that is at least 65% identical to
the amino acid sequence of SEQ ID NO: 4, domain III com
prises an amino acid sequence that is at least 50% identical to
the amino acid sequence of SEQ ID NO: 5, domain IV com
prises an amino acid sequence that is at least 80% identical to

ing of the corresponding zones (panel A). Increasing amounts
50

2000 g whole-cell lysate and the incorporation of radiola
beled FPP into squalene and botryococcene determined by
TLC separation/scintillation counting (panel B). B. braunii
2000 g whole-cell lysates were prepared from cells collected
55

containing 10 pg of protein were incubated without (—) or

tical to the amino acid sequence of SEQ ID NO: 7. In some
60

mined (panel C). The SSL-1 gene containing a 5' terminal
sequence coding for a hexa-histidine tag was over-expressed
in E. coli and the corresponding enzyme puri?ed by cobalt

a?inity chromatography according to the manufacturer

BRIEF DESCRIPTION OF THE DRAWINGS
65

FIG. 1A includes an overview of the hydrocracking pro
cess of a typical C34 botryococcene to yield fuel suitable for

at the indicated times (weeks) after subculturing, and aliquots

with (+) 1 pg of puri?ed SSL-1 protein, and incorporation of
radiolabeled FPP into squalene and botryococcene deter

the amino acid sequence of SEQ ID NO: 6, and domain V
comprises an amino acid sequence that is at least 40% iden

embodiments of the kit, the ?rst polypeptide is provided in a
?rst container, and the second polypeptide is provided in a
second container.

of puri?ed SSL-1 were incubated with 10 pg of B. braunii

(Sigma). B. braunii lysate was prepared from cells collected
at the indicated stages of culture development according to
the procedure described by Okada, S. et al. (Arch Biochem
Biophys 422: 110-118) and 10 pg of lysate protein was used
per assay. Assays were incubated at 37° C. for 1 h, then the

US 8,822,187 B1
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reaction products extracted with hexane. Aliquots of the hex

26.5 ((CH3)2C:CHCH2), 26.9 (CH2C(CH3):CHCH2),
39.8 (CH2C(CH3):CHCH2), 39.9 (CH2C(CH3):
CHCH2O), 66.6 (CH2C(CH3):CHCHZO), 121.3 (CH2C
(CH3):CHCH2O), 124.1 ((CH3)2C:CHCH2), 124.5
(CH2C(CH3):CHCH2), 131.5 ((CH3)2C:CHCH2), 135.4
(CH2C(CH3):CHCH2), and 140.2 (CH2C(CH3):

ane extracts was separated by silica TLC and the radioactivity
migrating to zones corresponding to authentic standards of

botryococcene and squalene determined by scintillation
counting. Data represents mean:s.e.m.
FIG. 5 depicts Michaelis-Menten enzyme kinetics of the
SSL-1 reaction. Enzyme assays (50 pl) were set up as
described in the methods section with puri?ed SSL-1 (0.2-1.0
pg), 0.1% triton X-100, 12 mM NADPH, and the indicated

CHCH2O).
FIG. 8 shows that SSL-3 and SSL-2 utilize PSPP, but not

concentration of 3 H-FPP. Assays were incubated for 15 min at

FPP, for ef?cient biosynthesis of botryococcene or squalene,
respectively. Two primary enzyme assays (500 pl) were set up

370 C. and stopped by addition of 50 pl 0.5 M EDTA. The

with 20 pg of puri?ed SSL-1 or Nicoliana benlhamiana

reactions were then extracted 3>< with 200 pl water saturated
1-butanol and pooled in a 4 ml glass screw cap vial. The
butanol was evaporated with a stream of nitrogen gas and the

were incubated at 37° C. for 1 h, then extracted 3>< with 500 pl

squalene synthase (TSS) plus 40 pM 3H-FPP. The assays
water saturated 1-butanol, pooled, and evaporated under a
stream of nitrogen gas. The white residue was resuspended in
50 pl of 25 mM NH4HCO3 in 70% ethanol (v/v). An aliquot of
the resuspension was analyzed by the acid phosphatase assay
(described in supplemental FIG. 4) and shown to consist of
45% and 40% PSPP for the SSL-1 and TSS primary incuba

white residue was resuspended in 2 ml of acid phosphatase

solution (20% 1-propanol (v/v), 100 mM sodium acetate pH
4.7, 0.1% Triton X-100, 10 units sweet potato acid phos
phatase) and incubated overnight (12-16 h) in a 28° C. shaker.
Dephosphorylated products were extracted 3>< with 1 ml
n-hexane, pooled, dried with a stream of nitrogen gas, and
resuspended in 200 pl of n-hexane. Aliquots of the hexane
extract were spotted onto reverse-phase TLC plates along
with standards of FOH and PSOH and developed with metha
nol:acetone (8:2). The standards were visualized with iodine
vapors and the zones corresponding to FOH (rf:0.65) and

20

tions, respectively. The remaining reaction product (55% and
60%, respectively) in both assays was FPP. It was calculated

that 1 pl of each resuspension contained ~150 pmoles of
3H-PSPP. Secondary enzyme assays (50 pl) were set up with
25

1 pl of the reaction products isolated from the primary incu
bations (~3 pM PSPP and ~4 pM FPP), 2 mM NADPH, and

PSOH (rf:0.45) were scraped and analyzed by scintillation

either 1 pg of SSL-3 or SSL-2 enzyme. For comparison,

spectroscopy. Addition of NADPH had no signi?cant effect

enzyme assays were also set up containing 3 pM 3H-FPP, 2
mM NADPH and either 1 pg each of SSL-1 plus SSL-3, or

on enzyme activity (less than 4% difference) and greater than
95% of the input radioactivity was recovered as FOH and

PSOH, indicating that PSPP is the only dominant reaction

30

product formed from FPP by the SSL-1 enzyme. The data was

analyzed using the SigmaPlot Enzyme Kinetics 1.3 software.
Data represents mean:S.E.M of duplicate assays with and
triplicate assays without NADPH.
FIG. 6 depicts the functional characterization of the
squalene synthase-like genes of Bolryococcus braunii race B.

35

addition of 50 pl 0.5 M EDTA, and extracted with 100 pl
n-hexane. Aliquots of the hexane extracts, along with stan
dards of squalene and botryococcene, were separated by
silica TLC using n-hexane as the developing solvent. Stan
dards were visualized with iodine vapors and the correspond

The squalene synthase-like genes, SSL-1, SSL-2 and SSL-3,
were expressed in yeast separately (SSL-1 (B), SSL-2(C) or
SSL-3(D)) or in combinations (SSL-1+SSL-2(E), SSL-1+

SSL-3 (F)) and the hexane extractable metabolites pro?led by
GC-MS. The chemical pro?le of yeast not engineered with

SSL-1 plus SSL-2. Additional control assays contained 5 pM
3H-FPP, 2 mM NADPH, and either 1 pg of SSL-3 or SSL-2.
The reactions were incubated at 370 C. for 15 min, stopped by

40

ing zones were analyzed by scintillation spectroscopy. Bot
ryococcene biosynthesis is shown in blue and squalene
biosynthesis is shown in red. Data represents mean:S.E.M.
FIG. 9 describes a proposed mechanism for bisfarnesyl
ether biosynthesis by SSL-2. When 2 molecules of FPP are
bound by the SSL-2 enzyme, ionization of the diphosphate

any gene constructs serves as the background control (A). The

SSL genes were also expressed in bacteria, the af?nity-tagged

substituent from one creates a carbocation, which can react

proteins puri?ed and assayed separately (SSL-2 (G)) or in
combinations (SSL-1+SSL-2 (H); SSL-1+SSL-3 (1)) for the

with a water molecule in close proximity to generate farnesol,
45

reaction products generated upon incubation with FPP and
pro?led by GC-MS (G-l), or for quantitative determination of
radio labeled FPP incorporated into speci?c reaction products

separated by TLC (J). Data (J) represents mean:S.E.M.
obtained from three independent experiments (n:3). The

FOH. If the FOH becomes appropriately positioned relative
to the second FPP molecule, then a Williamson ether synthe
sis (32) reaction could occur to yield bisfarnesyl ether.

FIG. 10 includes a comparison of botryococcene produc
tion in yeast engineered with different con?gurations of
50

SSL-1 and SSL-3. Yeast line TN7 was engineered with the

behavior of botryococcene (1), squalene (2), presqualene

SSL-1 and SSL-3 genes on separate plasmids (squares), with
gene fusions (SSL-1 fused to SSL-3 via a triplet repeat of

alcohol (3) and bisfarnesyl ether (4).

GGSG (triangles), or vice versa (diamonds)), or with 63 or 71

chromatograms (A-l) are also annotated for the elution

The MS for the dominant peak compounds with retention

amino acids of the carboxy terminus of the Bolryococcus
squalene synthase, sequences containing a membrane span
ning domain, appended to the carboxy termini of the SSL-1
and SSL-3 enzymes, respectively (circles). The data repre

time of 8.38 min in panels A and B are shown in panels C and

sents mean:S.E.M.

FIG. 7 includes GC chromatographs of unknown terpene

puri?ed from yeast overexpressing the SSL-2 gene (A) in

55

comparison to chemically synthesized bisfarnesyl ether (B).

D, respectively. Chemically synthesized bisfarnesyl ether
produced identical NMR spectrums to the unknown terpene
puri?ed from yeast over-expressing the SSL-2 gene:

1H NMR (400 MHz, CDC13) 61.58 (br s, 6), 1.64-1.66 (m,
18), 1.92-2.14 (m, 16), 3.96 (d, 1:6.8 Hz, 4), 5.04-5.12 (m, 4),
5.32-5.38 (m, 2);
13C NMR (100 MHz, CDC13) 6 16.2 (CH2C(CH3):
CHCH2), 16.7 (CH2C(CH3):CHCH2O), 17.9 (Z4CH3 of
(CH3)2C:CHCH2), 25.9 (E-CH3 of (CH3)2C:CHCH2),

FIG. 11 depicts the catalytic roles of the squalene synthase
60

65

like enzymes in Bolryococcus braunii race B and their puta
tive contributions to the triterpene constituents that accumu

late. The previously identi?ed squalene synthase gene (BSS)
(31) is thought to provide squalene essential for sterol
metabolism, whereas the squalene synthase-like genes SSL
1, SSL-2 and SSL-3 provide for the triterpene oils serving
specialized functions for the algae. In combination with SSL
1, SSL-2 could provide squalene for extracellular matrix and
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methylated squalene derivatives, while SSL-l plus SSL-3
generates botryococcene, which along with its methyl deriva

other embodiments, will be evident to those of ordinary skill
in the art after a study of the information provided in this
document. The information provided in this document, and

tives, accounts for the majority of the triterpene oil.

particularly the speci?c details of the described exemplary
embodiments, is provided primarily for cleamess of under

BRIEF DESCRIPTION OF THE SEQUENCE

standing and no unnecessary limitations are to be understood

LISTING

therefrom. In case of con?ict, the speci?cation of this docu

ment, including de?nitions, will control.
Some of the polynucleotide and polypeptide sequences

SEQ ID NO: 1 is a nucleic acid sequence for Bolryococcus

braunii race B squalene synthase-like 1 (SSL-l).
SEQ ID NO: 2 is an amino acid sequence for SSL-l.
SEQ ID NO: 3 is an amino acid sequence for Domain I of
SSL-1.
SEQ ID NO: 4 is an amino acid sequence for Domain II of
SSL-1.
SEQ ID NO: 5 is an amino acid sequence for Domain III of
SSL-1.
SEQ ID NO: 6 is an amino acid sequence for Domain IV of
SSL-1.
SEQ ID NO: 7 is an amino acid sequence for DomainV of
SSL-1.
SEQ ID NO: 8 is a nucleic acid sequence for Bolryococcus

10

PEPT® accession numbers. The sequences cross-referenced
in the GENBANK®/GENPEPT® database are expressly
incorporated by reference as are equivalent and related
sequences present in GENBANK®/GENPEPT® or other
15

PEPT® database associated with the sequences disclosed
herein. Unless otherwise indicated or apparent, the references
to the GENBANK®/GENPEPT® database are references to
20

otide primers.

The following are relevant GENBANK® accession num

bers: Bolryococcus braunii race B squalene synthase-like 1
25

?cations to embodiments described in this document, and

(SSL-l), -2 (SSL-2), and 3 (SSL-3), respectively,
iHQ585058; HQ585059, and HQ585060.
While the terms used herein are believed to be well under
stood by one of ordinary skill in the art, de?nitions are set

forth to facilitate explanation of the presently-disclosed sub
ject matter.
30

Unless de?ned otherwise, all technical and scienti?c terms
used herein have the same meaning as commonly understood

by one of ordinary skill in the art to which the presently

disclosed subject matter belongs. Although any methods,
35

devices, and materials similar or equivalent to those described
herein can be used in the practice or testing of the presently

disclosed subject matter, representative methods, devices,
and materials are now described.

Following long-standing patent law convention, the terms
“a”, “an”, and “the” refer to “one or more” when used in this
40

application, including the claims. Thus, for example, refer
ence to “a cell” includes a plurality of such cells, and so forth.

Unless otherwise indicated, all numbers expressing quan
tities of ingredients, properties such as reaction conditions,
and so forth used in the speci?cation and claims are to be
45

understood as being modi?ed in all instances by the term
“about”. Accordingly, unless indicated to the contrary, the
numerical parameters set forth in this speci?cation and claims
are approximations that can vary depending upon the desired

properties sought to be obtained by the presently-disclosed
50

subject matter.
As used herein, the term “about,” when referring to a value
or to an amount of mass, weight, time, volume, concentration
or percentage is meant to encompass variations of in some

55

embodiments:20%, in some embodiments 110%, in some
embodiments 15%, in some embodiments 11%, in some
embodiments 10.5%, and in some embodiments 10.1% from
the speci?ed amount, as such variations are appropriate to

perform the disclosed method. By way of providing an
example, about 60% is inclusive of: 60%:0.1%, which is
60

inclusive of 59.9%-60.1%, and so forth.
As used herein, ranges can be expressed as from “about”

one particular value, and/or to “about” another particular

DESCRIPTION OF EXEMPLARY
EMBODIMENTS
The details of one or more embodiments of the presently
disclosed subject matter are set forth in this document. Modi

the most recent version of the database as of the ?ling date of

this Application.

cus squalene synthase (BSS).
SEQ ID NO: 23 is an amino acid sequence for Domain I of
BSS.
SEQ ID NO: 24 is an amino acid sequence for Domain II of
BSS.
SEQ ID NO: 25 is an amino acid sequence for Domain III
of BSS.
SEQ ID NO: 26 is an amino acid sequence for Domain IV
of BSS.
SEQ ID NO: 27 is an amino acid sequence for DomainV of
BSS.
SEQ ID NOS: 28-45 are nucleic acid sequences for nucle

public databases. Also expressly incorporated herein by ref
erence are all annotations present in the GENBANK®/GEN

braunii race B squalene synthase-like 2 (SSL-2).
SEQ ID NO: 9 is an amino acid sequence for SSL-2.
SEQ ID NO: 10 is an amino acid sequence for Domain I of
SSL-2.
SEQ ID NO: 1 1 is an amino acid sequence for Domain II of
SSL-2.
SEQ ID NO: 12 is an amino acid sequence for Domain III
of SSL-2.
SEQ ID NO: 13 is an amino acid sequence for Domain IV
of SSL-2.
SEQ ID NO: 14 is an amino acid sequence for DomainV of
SSL-2.
SEQ ID NO: 15 is a nucleic acid sequence for Bolryococ
cus braunii race B squalene synthase-like 2 (SSL-3).
SEQ ID NO: 16 is an amino acid sequence for SSL-3.
SEQ ID NO: 17 is an amino acid sequence for Domain I of
SSL-3.
SEQ ID NO: 18 is an amino acid sequence for Domain II of
SSL-3.
SEQ ID NO: 19 is an amino acid sequence for Domain III
of SSL-3.
SEQ ID NO: 20 is an amino acid sequence for Domain IV
of SSL-3.
SEQ ID NO: 21 is an amino acid sequence for DomainV of
SSL-3.
SEQ ID NO: 22 is an amino acid sequence for Bolryococ

disclosed herein are cross-referenced to GENBANK®/GEN

value. It is also understood that there are a number of values
65

disclosed herein, and that each value is also herein disclosed
as “about” that particular value in addition to the value itself.

For example, if the value “10” is disclosed, then “about 10” is
also disclosed. It is also understood that each unit between
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two particular units are also disclosed. For example, if 10 and
15 are disclosed, then 11, 12, 13, and 14 are also disclosed.

The presently-disclosed subject matter includes polypep
tides, nucleic acid molecules, vectors, transfected cells, and

lated amino acid, an acylated amino acid, a pegylated amino
acid, a biotinylated amino acid, a carboxylated amino acid, a
phosphorylated amino acid, and the like. References
adequate to guide one of skill in the modi?cation of amino

methods for their use. The polypeptides of the presently

acids are replete throughout the literature. Example protocols

disclosed subject matter include, for example, polypeptides

are found in Walker (1998) Protein Protocols on CD-ROM

comprising the amino acid sequence set forth in SEQ ID NO:
2, 9, or 16, and fragments thereof. In some embodiments, the

(Humana Press, Towata, N.J.).
In some embodiments, the polypeptides of the presently
disclosed subject matter include up to 35, 25, 10, 5, 4, 3, 2 or

polypeptide fragments have triterpene synthase activity.

1 non-conservative amino acid substitutions.

In some embodiments, the polypeptides comprise one or

Recombinant methods for producing and isolating the trit
erpene synthase polypeptides and modi?ed triterpene syn
thase polypeptides of the presently-disclosed subject matter

more peptide domains I, II, III, IV, V and IV, wherein domain

I comprises LPQELQDPICIFYL (SEQ ID NO: 3), LPDEL
RHPICVFYL (SEQ ID NO: 10), or LPEVLQDPICVNYL
(SEQ ID NO: 17); domain II comprises LRALDTVED
DMNLKSETK (SEQ ID NO: 4), LRALDTVEDDMNLP
NEVK (SEQ ID NO: 11), or LRGLDTLQDDMAIPAEKR
(SEQ ID NO: 18); domain III comprises YCHYVAGSCGIA
VTKVIV (SEQ ID NO: 5), YCHYVAGLVGSAVAKIFV
(SEQ ID NO: 12), or YAFTNNGPVAICLTKLWV (SEQ ID

NO: 19); domain IV comprises GLLLQKANIITDYNED
(SEQ ID NO: 6), GQFLQKTNVIRDYLED (SEQ ID NO:

are described herein. In addition to recombinant production,

the polypeptides may be produced by direct peptide synthesis
using solid-phase techniques (e.g., Stewart et al. (1969)
Solid-Phase Peptide Synthesis (WH Freeman Co, San Fran
cisco); and Merri?eld (1963) J. Am. Chem. Soc. 85: 2149
20

2154; each of which is incorporated by reference). Peptide
synthesis may be performed using manual techniques or by
automation. Automated synthesis may be achieved, for

13), or AMFLGKINVIRDIKED (SEQ ID NO: 20); and

example, using Applied Biosystems 431A Peptide Synthe

domainV comprises ALALLLVTAFGHLS (SEQ ID NO: 7),

sizer (Perkin Elmer, Foster City, Calif.) in accordance with
the instructions provided by the manufacturer.

SCLIPEVMGLRTLT (SEQ ID NO: 14), or FCAVPELMS

LATIS (SEQ ID NO: 21).
The polypeptides of the presently-disclosed subject matter

25

A “protein” or “polypeptide”, which terms are used inter
changeably herein, comprises one or more chains of chemical

presence of modi?ed amino acids can be advantageous in, for

building blocks called amino acids that are linked together by
chemical bonds called peptide bonds. An “enzyme” means

example, increasing triterpene synthase catalytic activity or
increasing polypeptide stability. Amino acid(s) are modi?ed,

30 catalyzes or promotes, more or less speci?cally, one or more

can also contain one or more modi?ed amino acids. The

any substance, composed wholly or largely of protein, that

for example, co-translationally or post-translationally during
recombinant production (e.g., N-linked glycosylation at

chemical or biochemical reactions. A “native” or “wild-type”

protein, enzyme, polynucleotide, gene, or cell, means a pro
tein, enzyme, polynucleotide, gene, or cell that occurs in

N-X-S/T motifs during expression in mammalian cells) or
modi?ed by synthetic means. Accordingly, a “mutant”, “vari
ant” or “modi?ed” protein, enzyme, polynucleotide, gene, or
cell, means a protein, enzyme, polynucleotide, gene, or cell,

nature (whose form predominates in natural populations).
35

that has been altered or derived, or is in some way different or

changed, from a parent protein, enzyme, polynucleotide,

3, 2 or 1 conservative amino acid substitutions.

gene, or cell. A mutant or modi?ed protein or enzyme is

usually, although not necessarily, expressed from a mutant

40

polynucleotide or gene.

A “parent” protein, enzyme, polynucleotide, gene, or cell,
is any protein, enzyme, polynucleotide, gene, or cell, from
which any other protein, enzyme, polynucleotide, gene, or
cell, is derived or made, using any methods, tools or tech

Accordingly, in various embodiments, isolated or recom

binant polypeptides comprising the amino acid sequence set
forth in SEQ ID NO: 2, SEQ ID NO: 9, and SEQ ID NO: 16
are provided. The polypeptides include up to 35, 25, 10, 5, 4,
“Conservative amino acid substitutions” or, simply, “con
servative variations” of a particular sequence refers to the
replacement of one amino acid, or series of amino acids, with
essentially identical amino acid or series of amino acids. One

of skill will recognize that individual substitutions, deletions

niques, and whether or not the parent is itself native or mutant.

or additions which alter, add or delete a single amino acid or
a percentage of amino acids in an encoded sequence result in

A parent polynucleotide or gene encodes for a parent protein

“conservative variations” where the alterations result in the

or enzyme.

deletion of an amino acid, addition of an amino acid, or
substitution of an amino acid with a functionally similar

A “mutation” means any process or mechanism resulting
in a mutant protein, enzyme, polynucleotide, gene, or cell.

45

50

amino acid.

Conservative substitution tables providing functionally

This includes any mutation in which a protein, enzyme, poly
nucleotide, or gene sequence is altered, and any detectable
change in a cell arising from such a mutation. Typically, a

similar amino acids are well known in the art. For example,
one conservative substitution group includes Alanine (A),

alterations arising within a protein-encoding region of a gene

Serine (S), and Threonine (T). Another conservative substi
tution group includes Aspartic acid (D) and Glutamic acid
(E). Another conservative substitution group includes Aspar
agine (N) and Glutamine (Q). Yet another conservative sub

as well as alterations in regions outside of a protein-encoding
sequence, such as, but not limited to, regulatory or promoter
sequences. A mutation in a gene can be “silent”, i.e., not

conservative substitution group includes Isoleucine, (I) Leu
cine (L), Methionine (M), and Valine (V). Another conserva

mutation occurs in a polynucleotide or gene sequence, by

point mutations, deletions, or insertions of single or multiple
nucleotide residues. A mutation includes polynucleotide
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stitution group includesArginine (R) and Lysine (K). Another
60

re?ected in an amino acid alteration upon expression, leading

tive substitution group includes Phenylalanine (F), Tyrosine

to a “sequence-conservative” variant of the gene. This gener

(Y), and Tryptophan (W).

ally arises because of degeneracy of the genetic code wherein

Thus, “conservative amino acid substitutions” of a listed

more than one codon codes for the same amino acid.

Non-limiting examples of a modi?ed amino acid include a
glycosylated amino acid, a sulfated amino acid, a prenlyated

(e. g., farnesylated, geranylgeranylated) amino acid, an acety
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polypeptide sequence (e.g., SEQ ID N012, SEQ ID NO: 8, or
SEQ ID NO: 15) include substitutions of a percentage, typi
cally less than 10%, of the amino acids of the polypeptide
sequence, with an amino acid of the same conservative sub

US 8,822,187 B1
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stitution group. Accordingly, a conservatively substituted
variation of a polypeptide of the presently-disclosed subject
matter can contain, for example, substitutions of 35, 25, 10, 5,

than those indicated as conserved may differ in a protein or
enzyme so that the percent protein or amino acid sequence

similarity between any two proteins of similar function may
vary and can be, for example, at least 30%, at least 50%, at
least 70%, at least 80%, at least 90%, at least 95%, at least

4, 3, 2 or 1 amino acid with an amino acid of the same
conservative substitution group.
It is understood that the addition of sequences that do not
alter the encoded activity of a nucleic acid molecule, such as
the addition of a non-functional or non-coding sequence, is a

98% or at least 99%, as determined according to an alignment

scheme.
Non-conservative modi?cations of a particular polypep

conservative variation of the basic nucleic acid molecule. The
“activity” of an enzyme is a measure of its ability to catalyze
a reaction, i.e., to “function”, and may be expressed as the rate

at which the product of the reaction is produced. For example,

tide are those which substitute any amino acid not character
ized as a conservative substitution. For example, any substi
tution which crosses the bounds of the six groups set forth
above. These include substitutions of basic or acidic amino

enzyme activity can be represented as the amount of product
produced per unit of time or per unit of enzyme (e.g., con

Val, lle, Leu or Met), aromatic amino acid for basic or acidic

acids for neutral amino acids, (e.g., Asp, Glu, Asn, or Gln for

centration or weight), or in terms of af?nity or dissociation

amino acids (e.g., Phe, Tyr or Trp forAsp, Asn, Glu or Gln) or

constants. As used interchangeably herein a “triterpene syn

any other substitution not replacing an amino acid with a like

thase activity”, “biological activity of triterpene synthase” or

amino acid. Basic amino acids include lysine (K), arginine
(R), histidine (H); acidic amino acids include aspartic acid

“functional activity of triterpene synthase”, refers to an activ

(D), glutamic acid (E); uncharged polar amino acids include

ity exerted by a triterpene synthase protein, polypeptide or
nucleic acid molecule on a triterpene synthase polypeptide
substrate, as determined in vivo, or in vitro, according to

20

glycine (G), asparagine (N), glutamine (Q), serine (S), threo
nine (T), tyrosine (Y), cysteine (C); nonpolar amino acids

standard techniques.

include alanine (A), valine (V), leucine (L), isoleucine (I),

One of skill in the art will appreciate that many conserva
tive substitutions of the nucleic acid constructs which are
disclosed herein yield a functionally identical construct. For

proline (P), phenylalanine (F), methionine (M), tryptophan
25

(W); beta-branched amino acids include threonine (T), valine
(V), isoleucine (I); aromatic amino acids include tyrosine

example, owing to the degeneracy of the genetic code, “silent

(Y), phenylalanine (F), tryptophan (W), histidine (H).

substitutions” (i.e., substitutions in a nucleic acid sequence
which do not result in an alteration in an encoded polypep
tide) are an implied feature of every nucleic acid sequence

A polynucleotide, polypeptide, or other component is “iso
lated” when it is partially or completely separated from com

which encodes an amino acid.
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Similarly, “conservative amino acid substitutions,” in

ponents with which it is normally associated (other proteins,
nucleic acid molecules, cells, synthetic reagents, etc.). A
nucleic acid molecule or polypeptide is “recombinant” when

which one or a few amino acids in an amino acid sequence are

it is arti?cial or engineered, or derived from an arti?cial or

substituted with different amino acids with highly similar
properties, are also readily identi?ed as being highly similar

engineered protein or nucleic acid molecule. For example, a

to a disclosed construct. Families of amino acid residues
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having similar side chains have been de?ned in the art. These
families include amino acids with basic side chains (e.g.,

polynucleotide that is inserted into a vector or any other
heterologous location, e.g., in a genome of a recombinant
organism, such that it is not associated with nucleotide

isoleucine, proline, phenylalanine, methionine, tryptophan),

sequences that normally ?ank the polynucleotide as it is
found in nature is a recombinant polynucleotide. A protein
expressed in vitro or in vivo from a recombinant polynucle
otide is an example of a recombinant polypeptide. Likewise,
a polynucleotide sequence that does not appear in nature, for
example a variant of a naturally occurring gene, is recombi

beta-branched side chains (e.g., threonine, valine, isoleucine)
and aromatic side chains (e. g., tyrosine, phenylalanine, tryp

which is separated from other nucleic acid molecules which

lysine, arginine, histidine), acidic side chains (e.g., aspartic
acid, glutamic acid), uncharged polar side chains (e.g., gly
cine, asparagine, glutamine, serine, threonine, tyrosine, cys
teine), nonpolar side chains (e.g., alanine, valine, leucine,

tophan, histidine). Such conservative variations of each dis
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nant. For example, an “isolated” nucleic acid molecule is one
45

the degeneracy of the genetic code, a multitude of nucleotide

sequences encoding modi?ed triterpene synthase polypep
tides of the presently-disclosed subject matter may be pro
duced, some of which bear substantial identity to the nucleic
acid sequences explicitly disclosed herein. For instance,
codons AGA, AGG, CGA, CGC, CGG, and CGU all encode
the amino acid arginine. Thus, at every position in the nucleic
acid molecules of the presently-disclosed subject matter
where an arginine is speci?ed by a codon, the codon can be
altered to any of the corresponding codons described above
without altering the encoded polypeptide. It is understood
that U in an RNA sequence corresponds to T in a DNA
sequence.
“Conservative variants” are proteins or enzymes in which a
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polar character, size, shape and charge. Amino acids other

lated” includes nucleic acid molecules which are separated
from the chromosome with which the genomic DNA is natu
rally associated. Typically, an “isolated” nucleic acid mol
ecule is free of sequences which naturally ?ank the nucleic
acid molecule (i.e., sequences located at the 5' and 3' ends of

the nucleic acid molecule) in the genomic DNA of the organ
ism from which the nucleic acid molecule is derived. For
55

example, in various embodiments, the isolated nucleic acid
molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1
kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally
?ank the nucleic acid molecule in genomic DNA of the cell
from which the nucleic acid molecule is derived. Moreover,
an “isolated” nucleic acid molecule, such as a cDNA mol
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ecule, can be substantially free of other cellular material, or

culture medium when produced by recombinant techniques,
or substantially free of chemical precursors or other chemi

cals when chemically synthesized.

given amino acid residue has been changed without altering
overall conformation and function of the protein or enzyme,
including, but not limited to, replacement of an amino acid
with one having similar properties, including polar or non

are present in the natural source of the nucleic acid molecule.

For example, with regards to genomic DNA, the term “iso

closed sequence are a feature of the polypeptides provided
herein.
It will be appreciated by those skilled in the art that due to
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In some embodiments, a polypeptide provided herein
includes amino acid residue substitutions that correspond to
positions in a particular sequence at least 80%, 85%, 90%,
95%, 98% or 99% of the time. In other words, the presently

